10-Q: BioAdaptives Q3 2025: Revenue Growth Amidst Rising Losses

BioAdaptives Inc. reported increased revenue in Q3 2025 driven by new product launches, but also saw a significant rise in net loss and faces substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the three months ended September 30, 2025, was $(379,502), a significant increase from $(37,649) for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $(734,552), compared to $(527,373) for the nine months ended September 30, 2024.
• Revenue for the three months ended September 30, 2025, was $4,632, up from $0 in the prior year, primarily due to limited sales of PawPa Regen dog treats.
• Revenue for the nine months ended September 30, 2025, decreased to $7,851 from $12,669 in the prior year.
• Operating expenses for the three months increased to $269,540 from $121,941, and for the nine months to $798,970 from $268,781, driven by general, administrative, and professional fees.
• Cash on hand as of September 30, 2025, was $59,273, down from $137,470 at December 31, 2024.
• The company has an accumulated deficit of $9,897,858 as of September 30, 2025, and faces substantial doubt about its ability to continue as a going concern.
• Total current assets decreased to $108,860 from $261,885, while total current liabilities decreased to $1,589,570 from $1,725,803.
• A gain on settlement of debt of $101,700 was recognized during the nine months ended September 30, 2025, from the conversion of convertible notes.

Sentiment

Score: 2

Explanation: The company faces significant financial challenges, including a substantial net loss, declining cash, and an accumulated deficit leading to a going concern warning. While new products are being launched, revenue generation remains minimal, and internal controls are ineffective. The default on debentures further highlights financial instability.

Positives

• Initiated revenue generation in Q3 2025 with $4,632, primarily from limited sales of PawPa Regen dog treats, compared to no revenue in Q3 2024.
• Successfully launched the MyndMed product and promotions, with positive results reported from personal trials and testing.
• PawPa Regen dog treats have started limited sales and are undergoing market testing, showing progress in product commercialization.
• Zeranovia, a weight loss supplement, is completing clinical trials with encouraging results, including participants losing 5 to 11 pounds in 7 to 10 days.
• Xcellara, a regenerative wellness solution, has demonstrated a positive effect on individuals challenged by chronic fatigue in market testing.
• Recognized a gain on settlement of debt of $101,700 during the nine months ended September 30, 2025, through the conversion of convertible notes.
• Derivative liabilities decreased to $967,406 from $1,053,249, and the change in fair value of derivative liabilities resulted in a smaller loss for the nine months ended September 30, 2025, compared to the prior year.

Negatives

• Net loss significantly increased to $(379,502) for the three months ended September 30, 2025, from $(37,649) in the prior year.
• Net loss for the nine months ended September 30, 2025, increased to $(734,552) from $(527,373) in the prior year.
• Total revenues for the nine months ended September 30, 2025, decreased to $7,851 from $12,669 in the prior year.
• Operating expenses substantially increased for both the three-month ($269,540 vs. $121,941) and nine-month ($798,970 vs. $268,781) periods, primarily due to general, administrative, and professional fees.
• Cash on hand decreased to $59,273 as of September 30, 2025, from $137,470 at December 31, 2024.
• The company has an accumulated deficit of $9,897,858, indicating a history of losses.
• Working capital deficiency worsened to $(1,480,710) as of September 30, 2025, from $(1,463,918) at December 31, 2024.
• Net cash used in operating activities increased to $(360,197) for the nine months ended September 30, 2025, from $(148,979) in the prior year.
• The company's internal control over financial reporting was deemed ineffective as of September 30, 2025, due to material weaknesses including inadequate segregation of duties and insufficient written policies.
• The company is in default on 12% Debentures issued in 2018, which were due in 2020 and extended to December 31, 2021.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to incurred losses since inception, an accumulated deficit of $9,897,858, and the requirement for additional capital for operational and marketing activities.
• Uncertainty regarding the company's ability to raise additional capital through future issuances of common stock.
• The success of the business plan beyond the next 12 months is contingent upon obtaining additional financing, which may not be available on acceptable terms or at all.
• Anticipated incurring some losses in the near future until all products are launched and reach maximum sales potential.
• Ineffective disclosure controls and procedures as of March 31, 2025, and ineffective internal control over financial reporting as of September 30, 2025.
• Material weaknesses in internal control over financial reporting include inadequate segregation of duties, ineffective risk assessment, and insufficient written policies and procedures for accounting and financial reporting.
• Remediation efforts for internal control weaknesses are largely dependent upon securing additional financing, and if unsuccessful, remediation may be adversely affected.
• Default on 12% Debentures issued in 2018, which were due in 2020 and extended to December 31, 2021, with an alternative resolution still being worked on.
• All outstanding debts are in default as of September 30, 2025, which could lead to accelerated repayment demands or other adverse actions by creditors.

Future Outlook

The company anticipates incurring some losses in the near future until all new products are fully launched and reach their maximum sales potential. Its ability to continue as a going concern is dependent upon successfully competing, operating profitably, and/or raising additional capital through debt and/or equity financing arrangements, as well as the sale of its various new product lines. Management plans to raise capital through equity markets to fund future operations, seek additional acquisitions, and generate revenue.

Management Comments

• We believe that increasing our marketing expenses will be critical to establishing sales sufficient to cover our costs and, if possible, generate a profit.
• Management's plans include raising capital through the equity markets to fund future operations, seeking additional acquisitions, and generating revenue through our business.
• Because of our limited staff size and the integration of our executives and directors into operations, the prospect of significant internal control failures resulting in unreliable financial statements or worse is remote.

Industry Context

BioAdaptives operates in the competitive nutraceutical and medical device sectors, focusing on natural plant, fungi, and algal-based products. The company's strategy to reformulate its product line and introduce new offerings like MyndMed (cognitive health), Zeranovia (weight loss), Xcellara (regenerative wellness), and PawPa Regen (pet care) aligns with growing consumer demand for natural health solutions and specialized wellness products. The emphasis on digital marketing, telehealth partnerships, and affiliate programs reflects current industry trends in direct-to-consumer sales and leveraging influencer networks. The weight loss product Zeranovia's positioning as a complement to GLP-1 and GIP treatments like Ozempic and Wegovy indicates an attempt to capitalize on a rapidly expanding and high-demand market segment.

Comparison to Industry Standards

• The company's significant accumulated deficit and 'going concern' warning are below industry standards for established, profitable companies.
• The reported revenue of $4,632 for Q3 2025 and $7,851 for the nine months ended September 30, 2025, is extremely low for a publicly traded company in the nutraceutical or medical device space, especially when compared to larger players like GNC, Herbalife, or even smaller, successful startups in the wellness sector that often achieve millions in revenue within their first few years of product launch.
• The substantial increase in operating expenses relative to minimal revenue growth suggests a high burn rate without corresponding sales traction, which is a concern compared to industry benchmarks for efficient capital deployment.
• The ineffectiveness of internal controls over financial reporting, including inadequate segregation of duties, is a significant governance weakness that falls short of best practices for public companies, regardless of size.
• The default on debentures indicates financial distress and a lack of adherence to debt obligations, which is a red flag compared to financially stable industry peers.
• While the product development pipeline (MyndMed, Zeranovia, Xcellara, PawPa Regen) shows potential, the current financial metrics do not reflect successful commercialization on a scale comparable to even emerging industry players.

Management Changes

Corporate Governance

Legal Proceedings

• No pending legal proceedings to which the company is a party, either individually or in the aggregate.
• No notification of any potential claims or disputes.

Related Party Transactions

• Employment agreement with the Chief Executive Officer (James E. Keener) in May 2024 for a salary of $300,000 per annum. During the nine months ended September 30, 2025, $225,000 payroll expense was recorded, and 40,413 shares of Series D Preferred Stock were issued for payroll.
• Employment agreement with a director in May 2024 for a salary of $5,000 per month. During the nine months ended September 30, 2025, $45,000 payroll expense was recorded, and 7,411 shares of Series D Preferred Stock were issued for payroll.
• Employment agreement with another director in January 2025 for a salary of $5,000 per month. During the nine months ended September 30, 2025, $40,000 payroll expense was recorded, and 6,462 shares of Series D Preferred Stock were issued for payroll.
• Grant of 500,000 shares of common stock as a stock option to a director on April 16, 2025, valued at $28,670, fully vested on grant date.

Stakeholder Impact

• Shareholders: Significant dilution risk from potential future equity raises and conversions of convertible notes. Existing shares are subject to substantial doubt about the company's ability to continue as a going concern, potentially leading to loss of investment. Ineffective internal controls could erode confidence.
• Employees: The company has one full-time executive employee and relies on hourly labor and consultants. The financial instability and going concern warning could impact job security and future compensation.
• Creditors: The company is in default on 12% Debentures and all outstanding debts, indicating a high risk of non-payment or delayed payment, potentially leading to legal action or further restructuring.
• Customers: New product launches (MyndMed, PawPa Regen, Zeranovia, Xcellara) could offer new health and wellness solutions, but the company's financial instability might raise concerns about long-term product availability and support.
• Suppliers: Financial instability and cash constraints could lead to delayed payments or difficulty in securing favorable terms for raw materials and services.

Next Steps

• Launch Zeranovia in the last quarter, following completion of its clinical trial.
• Increase marketing expenses to establish sales sufficient to cover costs and generate profit.
• Raise capital through equity markets to fund future operations.
• Seek additional acquisitions.
• Generate revenue through new product lines.
• Appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management.
• Adopt sufficient written policies and procedures for accounting and financial reporting.
• Work on an alternative resolution for the defaulted 12% Debentures.

Key Dates

Recommendation

The company is in a precarious financial position, evidenced by a substantial accumulated deficit, increasing net losses, declining cash reserves, and a 'going concern' warning from its auditors. Its internal controls are ineffective, and it has defaulted on existing debt obligations. While there are new product launches, revenue generation remains minimal and insufficient to cover escalating operating expenses. The high risk of further dilution from necessary capital raises, coupled with fundamental operational and financial weaknesses, makes this a high-risk investment with significant downside potential. A seasoned investor would likely view the current situation as unsustainable without a drastic and immediate turnaround, which is not clearly outlined or guaranteed.

Keywords

BioAdaptives Inc., SEC 10-Q, Quarterly Report, Nutraceuticals, Dietary Supplements, Medical Devices, Cognitive Health, Weight Loss, Pet Wellness, PawPa Regen, MyndMed, Zeranovia, Xcellara, Going Concern, Financial Performance, Net Loss, Revenue, Capital Raise, Internal Controls, Convertible Notes, Derivative Liabilities